Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 27%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group is a promising investment due to their innovative and revolutionary product, the Organ Care System. With a strong focus on expanding their operations in Europe and the potential for growth in their OCS Kidney program, the company is well-positioned for continued success. Additionally, their core liver franchise and aviation sector show strong performance, and the company is projected to see significant revenue growth in the coming years. Overall, TransMedics' focus on differentiated clinical outcomes and superior logistics make it a strong choice for potential investors.

Bears say

TransMedics Group is currently facing a variety of challenges that may have a negative impact on its stock performance. This includes the historically slow market growth during Q4, weak donor activity at the beginning of 2026, and the potential disruption from CMS' OPO modernization initiatives in the second half of the year. Furthermore, while the company has developed a strong product portfolio with the OCS, ENHANCE Part B, DENOVO, CHOPS, OCS kidney, and international expansion, the success and adoption of these initiatives are not guaranteed and may not have a significant impact on the company's financials until 2027. Additionally, the company's recent increase in operating expenses and its decision to exercise a $375M purchase option for its new HQ may also have a negative impact on its profitability in the near term. Overall, these factors may lead to slower revenue growth and less enthusiastic market sentiment in the coming months, making it difficult for TransMedics Group to meet its revenue and margin targets.

TMDX has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 27% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 11 analysts, TMDX has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $118.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $118.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.